19F MRI of Ventilation in Subjects With Cystic Fibrosis Undergoing Treatment for Pulmonary Exacerbation

Phase 0 Terminated 5 enrolled University of North Carolina, Chapel Hill National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collab

NaSingle-groupOpen-labelOther

Summary

The purpose of this study is to use perfluorinated gas imaging to highlight regions of functional variation within the lungs of participants with cystic fibrosis (CF), and to correlate this with changes in spirometry, lung clearance index, and quality of life of CF subjects undergoing treatment for a pulmonary exacerbation.

Timeline

Start: 2015-08-25
Primary completion: 2019-09-13
Completion: 2019-09-13

Outcome

Outcome not reported

Stopped (Enrollment): “Enrollment barriers made study completion impossible”

Publications

Background Halaweish AF, Moon RE, Foster WM, Soher BJ, McAdams HP, MacFall JR, Ainslie MD, MacIntyre NR, Charles HC. Perfluoropropane gas as a magnetic resonance lung imaging contrast agent in humans. Chest. 2013 Oct;144(4):1300-1310. doi: 10.1378/chest.12-2597.
Background Couch MJ, Ball IK, Li T, Fox MS, Littlefield SL, Biman B, Albert MS. Pulmonary ultrashort echo time 19F MR imaging with inhaled fluorinated gas mixtures in healthy volunteers: feasibility. Radiology. 2013 Dec;269(3):903-9. doi: 10.1148/radiol.13130609. Epub 2013 Oct 28.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PFP	Unknown	—	Inhaled